| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Adi Malkoff, Abraham Weizman, Illana Gozes, Moshe Rehav. Decreased M1 muscarinic receptor density in rat amphetamine model of schizophrenia is normalized by clozapine, but not haloperidol. Journal of neural transmission (Vienna, Austria : 1996). vol 115. issue 11. 2009-01-06. PMID:18806925. |
decreased m1 muscarinic receptor density in rat amphetamine model of schizophrenia is normalized by clozapine, but not haloperidol. |
2009-01-06 |
2023-08-12 |
rat |
| Agata Faron-Górecka, Andrzej Górecki, Maciej Kuśmider, Zygmunt Wasylewski, Marta Dziedzicka-Wasylewsk. The role of D1-D2 receptor hetero-dimerization in the mechanism of action of clozapine. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. vol 18. issue 9. 2008-12-18. PMID:18550344. |
clozapine is effective although still not perfect drug used to treat schizophrenia. |
2008-12-18 |
2023-08-12 |
Not clear |
| U E Lang, M Willbring, R von Golitschek, A Schmeisser, K Matschke, S Malte Tugteki. Clozapine-induced myocarditis after long-term treatment: case presentation and clinical perspectives. Journal of psychopharmacology (Oxford, England). vol 22. issue 5. 2008-12-16. PMID:18308817. |
clozapine is the drug of choice for treatment-resistant schizophrenia. |
2008-12-16 |
2023-08-12 |
Not clear |
| Philip D Harvey, Emilio Sacchetti, Alessandro Galluzzo, Fabio Romeo, Barbara Gorini, Robert M Bilder, Antony D Loebe. A randomized double-blind comparison of ziprasidone vs. clozapine for cognition in patients with schizophrenia selected for resistance or intolerance to previous treatment. Schizophrenia research. vol 105. issue 1-3. 2008-12-11. PMID:18077136. |
a randomized double-blind comparison of ziprasidone vs. clozapine for cognition in patients with schizophrenia selected for resistance or intolerance to previous treatment. |
2008-12-11 |
2023-08-12 |
Not clear |
| Philip D Harvey, Emilio Sacchetti, Alessandro Galluzzo, Fabio Romeo, Barbara Gorini, Robert M Bilder, Antony D Loebe. A randomized double-blind comparison of ziprasidone vs. clozapine for cognition in patients with schizophrenia selected for resistance or intolerance to previous treatment. Schizophrenia research. vol 105. issue 1-3. 2008-12-11. PMID:18077136. |
this study compared the cognitive benefits of clozapine and ziprasidone in schizophrenia patients (n=130) with a history of either failure to respond to or intolerance of previous adequate antipsychotic treatments. |
2008-12-11 |
2023-08-12 |
Not clear |
| A R van Gool, M T van der Velden, A W Oosten, E van Meerten, W M A Verhoeven, A J M Loone. [Chemotherapy during clozapine treatment. Increased risk of agranulocytosis?]. Tijdschrift voor psychiatrie. vol 50. issue 10. 2008-12-01. PMID:18951346. |
however, she was using clozapine for the treatment of schizophrenia. |
2008-12-01 |
2023-08-12 |
Not clear |
| Jirí Masopust, Ivan Tůma, Jan Libige. Adjunctive aripiprazole decreased metabolic side effects of clozapine treatment. Neuro endocrinology letters. vol 29. issue 4. 2008-11-12. PMID:18766167. |
clozapine is an atypical antipsychotic indicated for the treatment of refractory schizophrenia. |
2008-11-12 |
2023-08-12 |
Not clear |
| b' Branka Aukst-Margeti\\xc4\\x87, Branimir Margeti\\xc4\\x8. Treatment of generalized tardive dystonia with clozapine. Psychiatria Danubina. vol 20. issue 3. 2008-11-12. PMID:18827758.' |
we report a case of a 35-year-old patient with schizophrenia who developed a generalized form of tardive dystonia after switching of clozapine to risperidone treatment that persisted after switch to olanzapine and during the period while treatment with an antipsychotic was discontinued. |
2008-11-12 |
2023-08-12 |
Not clear |
| Shunsuke Maehara, Hirohiko Hikichi, Akio Satow, Shoki Okuda, Hisashi Oht. Antipsychotic property of a muscarinic receptor agonist in animal models for schizophrenia. Pharmacology, biochemistry, and behavior. vol 91. issue 1. 2008-11-06. PMID:18651995. |
in addition to modulating hyperdopaminergic function, oxotremorine as well as clozapine (3-10 mg/kg) reversed the disruption of ppi caused by ketamine, an n-methyl-d-aspartate antagonist in rats, which mimics the clinical symptoms of schizophrenia. |
2008-11-06 |
2023-08-12 |
mouse |
| M Fendt, A Lex, P Falkai, F A Henn, A Schmit. Behavioural alterations in rats following neonatal hypoxia and effects of clozapine: implications for schizophrenia. Pharmacopsychiatry. vol 41. issue 4. 2008-11-05. PMID:18651342. |
behavioural alterations in rats following neonatal hypoxia and effects of clozapine: implications for schizophrenia. |
2008-11-05 |
2023-08-12 |
rat |
| Sanjiv Kumra, Harvey Kranzler, Ginny Gerbino-Rosen, Hana M Kester, Courtney DeThomas, Kathyrn Cullen, James Regan, John M Kan. Clozapine versus "high-dose" olanzapine in refractory early-onset schizophrenia: an open-label extension study. Journal of child and adolescent psychopharmacology. vol 18. issue 4. 2008-10-27. PMID:18759640. |
clozapine versus "high-dose" olanzapine in refractory early-onset schizophrenia: an open-label extension study. |
2008-10-27 |
2023-08-12 |
Not clear |
| Sanjiv Kumra, Harvey Kranzler, Ginny Gerbino-Rosen, Hana M Kester, Courtney DeThomas, Kathyrn Cullen, James Regan, John M Kan. Clozapine versus "high-dose" olanzapine in refractory early-onset schizophrenia: an open-label extension study. Journal of child and adolescent psychopharmacology. vol 18. issue 4. 2008-10-27. PMID:18759640. |
a recent 12-week controlled comparison demonstrated the superiority of clozapine to "high-dose" olanzapine in adolescents with treatment-refractory schizophrenia. |
2008-10-27 |
2023-08-12 |
Not clear |
| Pietro Gareri, Pasquale De Fazio, Emilio Russo, Norma Marigliano, Salvatore De Fazio, Giovambattista De Sarr. The safety of clozapine in the elderly. Expert opinion on drug safety. vol 7. issue 5. 2008-10-27. PMID:18759705. |
clozapine was the first atypical 'broad spectrum' antipsychotic drug to be marketed and the first agent approved for the treatment of schizophrenia refractory to other medications. |
2008-10-27 |
2023-08-12 |
Not clear |
| Ju-Feng Wang, Jiang-Yong Min, Thomas G Hampton, Ivo Amende, Xinhua Yan, Sohail Malek, Walter H Abelmann, Alan I Green, John Zeind, James P Morga. Clozapine-induced myocarditis: role of catecholamines in a murine model. European journal of pharmacology. vol 592. issue 1-3. 2008-10-24. PMID:18627770. |
clozapine, an atypical antipsychotic, is very effective in the treatment of resistant schizophrenia. |
2008-10-24 |
2023-08-12 |
mouse |
| Badira Makhoul, Irit Hochberg, Shmuel Rispler, Zaher S Azza. Dilated cardiomyopathy: an unusual complication of clozapine therapy. Nature clinical practice. Cardiovascular medicine. vol 5. issue 9. 2008-10-23. PMID:18628775. |
he had a history of chronic residual schizophrenia for which he had been taking clozapine for 7 years, but had no known prior cardiac disease. |
2008-10-23 |
2023-08-12 |
Not clear |
| Ali Doruk, Ozcan Uzun, Aytekin Ozşahi. A placebo-controlled study of extract of ginkgo biloba added to clozapine in patients with treatment-resistant schizophrenia. International clinical psychopharmacology. vol 23. issue 4. 2008-10-17. PMID:18545061. |
a placebo-controlled study of extract of ginkgo biloba added to clozapine in patients with treatment-resistant schizophrenia. |
2008-10-17 |
2023-08-12 |
Not clear |
| Ali Doruk, Ozcan Uzun, Aytekin Ozşahi. A placebo-controlled study of extract of ginkgo biloba added to clozapine in patients with treatment-resistant schizophrenia. International clinical psychopharmacology. vol 23. issue 4. 2008-10-17. PMID:18545061. |
the focus of this study was the systematic evaluation of the clinical effects of the extract of ginkgo biloba (egb) as an adjunct to the atypical antipsychotic clozapine in the treatment of refractory schizophrenia. |
2008-10-17 |
2023-08-12 |
Not clear |
| Ali Doruk, Ozcan Uzun, Aytekin Ozşahi. A placebo-controlled study of extract of ginkgo biloba added to clozapine in patients with treatment-resistant schizophrenia. International clinical psychopharmacology. vol 23. issue 4. 2008-10-17. PMID:18545061. |
these preliminary data suggested that egb was found useful for enhancing the effect of clozapine on negative symptoms in patients with treatment-resistant schizophrenia. |
2008-10-17 |
2023-08-12 |
Not clear |
| Luca Pani, José M Villagrán, Vassilis P Kontaxakis, Köksal Alpteki. Practical issues with amisulpride in the management of patients with schizophrenia. Clinical drug investigation. vol 28. issue 8. 2008-10-17. PMID:18598092. |
the pharmacological and clinical profiles of amisulpride suggest that this agent is a viable clinical option when a change of antipsychotic therapy is required in patients with schizophrenia because of lack of efficacy, adverse events and poor adherence to treatment, or for augmentation of clozapine in treatment-resistant illness. |
2008-10-17 |
2023-08-12 |
Not clear |
| Rebecca Syed, Katie Au, Caroline Cahill, Lorna Duggan, Yanling He, Victor Udu, Jun Xi. Pharmacological interventions for clozapine-induced hypersalivation. The Cochrane database of systematic reviews. issue 3. 2008-10-15. PMID:18646130. |
clozapine is widely used for people with schizophrenia. |
2008-10-15 |
2023-08-12 |
Not clear |